Market Overview

According to Metastat Insight-style structured analysis, Global focused ultrasound system for neurosurgery market is valued at USD 55,115.3 thousand in 2025 and is projected to reach USD 95,645.5 thousand by 2032, exhibiting a CAGR of 7.9% during the forecast period.

The market is driven by the rising demand for minimally invasive neurosurgical procedures, particularly for treating essential tremor and Parkinson's disease, utilizing MRI-guided focused ultrasound technology.

Major Players Profiled in the Market Report:

• BrainSonix Corporation

• Carthera S.A.

• FUS Instruments Inc.

• INSIGHTEC Ltd.

• NaviFUS Corporation

• Neurosona Co., Ltd.

• Sonic Concepts, Inc. (NeuroFUS)

Segments

Hospitals Leading Adoption

By End User, the market is divided into Hospitals, Laboratories, and Specialty Clinics.

Hospitals represent the largest end-user segment, valued at over USD 41,215.8 thousand in 2025. Neurosurgery departments are adopting MRI-guided systems for better clinical outcomes and faster recovery times compared to traditional surgery.

Specialty Clinics Offering Outpatient Solutions

Specialty Clinics, valued at around USD 7,060.1 thousand in 2025, are growing due to the non-invasive nature of the treatment, catering to outpatients with conditions like neuropathic pain and tremors.

Laboratories Driving Innovation

Research Laboratories account for over USD 6,839.3 thousand, fueled by academic research into neuromodulation and drug delivery applications, supported by government funding.

Source :- https://www.metastatinsight.com/report/focused-ultrasound-system-for-neurosurgery-market

Report Coverage

The report offers:

• Major growth drivers, restraints, opportunities, and challenges

• Comprehensive regional insights and market valuation

• List of key industry players and their competencies

• Key strategies such as clinical research expansion and technological refinement

• Analysis of trends across all submarkets, including potential applications in Alzheimer's and stroke

Drivers & Restraints

Drivers

Demand for Minimally Invasive Procedures

The need for safer alternatives to open brain surgery and radiation therapy is a primary growth driver. Focused ultrasound offers reduced risks, shorter hospital stays, and improved quality of life for patients.

Technological Advancements

Continuous improvements in MRI and robotic guidance enhance the precision of focused ultrasound, expanding its applicability to various neurological disorders.

Restraints

High System Costs

The significant expense of acquiring and maintaining focused ultrasound systems limits adoption, particularly in developing regions.

Regulatory Hurdles

Complex and stringent regulatory pathways for new medical devices can delay commercialization and market entry.

Opportunities

Expansion of Clinical Applications

There is significant potential in expanding treatment to conditions like Alzheimer’s, epilepsy, and stroke. Ongoing research and collaborations aim to build clinical evidence for these new applications.

Regional Insights

North America

Dominates the market due to early regulatory approvals (FDA) and a strong presence of key players like INSIGHTEC. The U.S. leads in clinical adoption for essential tremor and Parkinson's treatments.

Europe

The second-largest market, driven by increasing neuroscience research investment and an aging population. Companies like Carthera have secured CE mark approvals for innovative applications.

Asia-Pacific

An emerging market with high growth potential due to rising demand for non-invasive neurosurgical techniques in densely populated countries.

South America

Includes Brazil, Argentina, and the Rest of South America.

Middle East & Africa

Categorized into GCC Countries, Egypt, South Africa, and the Rest of the Middle East & Africa.

Competitive Landscape

The market features pioneering companies like INSIGHTEC Ltd. and Carthera S.A. leading innovation. Companies are focused on:

• Developing fully integrated platforms like Exablate Neuro for incision-less surgery

• Creating intraoperative ultrasound devices (e.g., SonoCloud) to optimize tumor resection

• Expanding clinical trials to validate new neuro-oncology and neuromodulation applications